Machina Capital S.A.S. lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 85.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,380 shares of the company’s stock after selling 7,807 shares during the period. Machina Capital S.A.S.’s holdings in IDEXX Laboratories were worth $721,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the stock. Bank of New York Mellon Corp purchased a new stake in IDEXX Laboratories during the 2nd quarter valued at about $628,223,000. Arrowstreet Capital Limited Partnership grew its position in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock worth $471,335,000 after acquiring an additional 288,471 shares during the last quarter. International Assets Investment Management LLC grew its position in IDEXX Laboratories by 30,484.1% during the 3rd quarter. International Assets Investment Management LLC now owns 234,274 shares of the company’s stock worth $122,336,000 after acquiring an additional 233,508 shares during the last quarter. Alyeska Investment Group L.P. increased its stake in IDEXX Laboratories by 97.3% in the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock worth $211,146,000 after purchasing an additional 197,808 shares during the period. Finally, American Capital Management Inc. purchased a new position in IDEXX Laboratories in the 2nd quarter worth approximately $85,341,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.
IDEXX Laboratories Stock Performance
IDEXX Laboratories stock opened at $704.23 on Monday. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. The firm has a market cap of $55.48 billion, a P/E ratio of 47.49 and a beta of 1.55. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The firm has a 50-day moving average of $562.41 and a 200-day moving average of $573.52.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.71 by $0.25. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. IDEXX Laboratories’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.22 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 15.05 EPS for the current year.
Analysts Set New Price Targets
IDXX has been the subject of several recent research reports. Jefferies Financial Group lowered their price objective on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research report on Tuesday, October 20th. Morgan Stanley raised their target price on shares of IDEXX Laboratories from $805.00 to $810.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a report on Friday, October 16th. Citigroup lifted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday, October 30th. They set a “buy” rating for the company. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $717.27.
Read Our Latest Stock Report on IDXX
Insider Transactions at IDEXX Laboratories
In related news, Director Daniel M. Junius sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $704.07, for a total transaction of $844,884.00. Following the completion of the transaction, the director owned 2,361 shares in the company, valued at $1,662,309.27. This represents a 33.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sharon E. Underberg sold 8,906 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $688.59, for a total value of $6,132,582.54. Following the transaction, the executive vice president owned 7,169 shares of the company’s stock, valued at approximately $4,936,501.71. This represents a 55.40% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 41,428 shares of company stock worth $28,567,934. Corporate insiders own 0.79% of the company’s stock.
About IDEXX Laboratories
IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.
Read More
- Five stocks we like better than IDEXX Laboratories
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
